美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物科技指数ETF-iShares Nasdaq

204.26

-2.2300-1.08%

盘前：204.260.00000.00%04:00 EDT

成交量：115.73万

成交额：2.37亿

市值：107.13亿

市盈率：32.36

高：206.93

开：206.85

低：203.92

收：206.49

52周最高：217.12

52周最低：149.09

股本：5,245.00万

流通股本：5,245.00万

量比：0.50

换手率：2.21%

股息：0.35

股息率：0.17%

每股收益(TTM):6.31

每股收益(LYR):35.34

净资产收益率：24.54%

总资产收益率：0.10%

市净率：1.32

市盈率(LYR):5.78

数据加载中...

总览公司新闻资讯公告

安进：Dazodalibep治疗中重度症状性干燥综合征的Oasiz 303三期研究预计2026年第四季度完成

福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性

福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组

福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效

公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发

福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价

创新药热度飙升，关注100%创新药研发标的

专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元

专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元

吉利德科学扩大六项免许可费自愿授权协议，力推每年一次HIV预防药Lenacapavir

Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发

百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼

百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进

吉利德科学携手巴西卫生部，共促Lenacapavir本地化生产新篇章

吉利德科学：持续探索与泛美卫生组织合作，助力各国准备好并扩大长效艾滋病预防措施的普及

吉利德科学公司高管在电话会议上表示，HIV药物市场的增长预计将在未来几个季度内回归至2%至3%的正常水平。

吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致

吉利德科学携手泛美卫生组织，加速拉美及加勒比地区HIV预防药物Lenacapavir的可及性

吉利德高管表示，未来几个季度HIV市场增长或将回归2%-3%常态水平

吉利德高管透露：周服HIV预防药物有望2027年第一季度上市

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IBB/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":204.26,"timestamp":1791835200000,"preClose":206.49,"halted":0,"volume":1157283,"hourTrading":{"tag":"盘前","latestPrice":204.26,"preClose":204.26,"latestTime":"04:00 EDT","volume":23,"amount":4696.87991,"timestamp":1791878436446,"change":0,"changeRate":0,"amplitude":0.000673},"delay":0,"changeRate":-0.010799554457843082,"floatShares":52450000,"shares":52450000,"eps":6.311863,"marketStatus":"盘前交易","change":-2.23,"latestTime":"10-13 04:07:31 EDT","open":206.85,"high":206.93,"low":203.92,"amount":237090797.56701,"amplitude":0.014577,"askPrice":205.94,"askSize":127,"bidPrice":203.75,"bidSize":300,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":204.26,"sharesOutstanding":49450000,"nav":206.296467,"aum":10840879340.85,"dividendRate":0.0017,"bidAskSpread":0.000349,"preHourTrading":{"tag":"盘前","latestPrice":204.26,"preClose":204.26,"latestTime":"04:00 EDT","volume":23,"amount":4696.87991,"timestamp":1791878436446,"change":0,"changeRate":0,"amplitude":0.000673},"postHourTrading":{"tag":"盘后","latestPrice":204.26,"preClose":204.26,"latestTime":"19:47 EDT","volume":10034,"amount":2049515.9148,"timestamp":1791848828793,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.501392,"impliedVol":0.2474,"impliedVolPercentile":0.704},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":52450000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":0.501392,"shares":52450000,"dividePrice":0.3472,"high":206.93,"amplitude":0.014577,"preClose":206.49,"low":203.92,"week52Low":149.0909,"pbRate":"1.32","psRate":"257.76","week52High":217.12,"institutionHeld":0,"latestPrice":204.26,"committee":0.405152,"eps":6.311863,"divideRate":0.0017,"volume":1157283,"delay":0,"ttmEps":6.311863,"open":206.85,"prevYearClose":168.77,"prevWeekClose":206.49,"prevMonthClose":210.53,"prevQuarterClose":210.53,"fiveDayClose":207.96,"twentyDayClose":204.6,"sixtyDayClose":189.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-07-02","value":0.15606,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1144298886","title":"安进：Dazodalibep治疗中重度症状性干燥综合征的Oasiz 303三期研究预计2026年第四季度完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1144298886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144298886?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082009,"startTime":"0","endTime":"0","summary":"安进（Amgen）披露，其针对中重度症状性干燥综合征（Sjögren's Disease）所开展的Dazodalibep三期临床研究——即Oasiz 303试验，预计将于2026年第四季度圆满完成。这一时间表的明确，为该公司在自身免疫疾病领域的管线推进提供了新的节点参照。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE0009355771.USD","LU2468319806.SGD","IBBQ","BK4585","LU0122379950.USD","IE00B2B36J28.USD","BK4588","BK4533","BK4139","LU2089984988.USD","BK4534","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4581","TBXU","BIB","LU0320765992.SGD","LU0058720904.USD","LU0889565916.HKD","BBH","IBB","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU1571399168.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU2242646821.SGD","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU1983299246.USD","LU2242652126.USD","PJP","BK4599","SG9999001440.SGD","IE00BJT1NW94.SGD","AMGN","LU2112291526.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050236","title":"福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196050236?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078535,"startTime":"0","endTime":"0","summary":"福泰制药近日披露，其候选药物Inaxaplin在两项针对APOL1介导肾病的临床试验队列中，表现出令人满意的安全性和耐受性特征。业内观察人士指出，Inaxaplin若能在后续研究中持续印证其价值，有望为AMKD这一难治性疾病带来突破性治疗选择。福泰制药此番公告，不仅回应了市场对管线进展的关切，也再次凸显了其在精准医疗赛道上的深耕意图。随着更多数据的积累，Inaxaplin的临床定位将愈发清晰，其对患者生活质量的实际改善程度也将接受更严苛的检验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0256863811.USD","GNMX","TBXU","LU1585245621.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2362541513.USD","LU0079474960.USD","PBE","SG9999013999.USD","SGXZ57979304.SGD","LU2089984988.USD","LU2362540622.SGD","LU1430594728.SGD","LU2417539215.USD","LU0417517546.SGD","IE0009355771.USD","IE0002270589.USD","BK4533","BK4567","BK4585","LU1093756325.SGD","LU2462157665.USD","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","LU0320765992.SGD","IE00B19Z9P08.USD","LU0823416689.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","VRTX","LU0234570918.USD","LU1674673428.USD","LU1778281490.HKD","SG9999001176.USD","IDNA","IE00BJJMRZ35.SGD","LU1069344957.HKD","LU2456880835.USD","IBB","LU0058720904.USD","LU2236285917.USD","BK4588","LU2362541273.HKD","LU0432979614.USD","LU1093756168.USD","LU2324357040.USD","SG9999001176.SGD","BBH","IE0002141913.USD","LU2237438978.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","LU1674673691.USD","IE00B894F039.SGD","IE00B19Z3581.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160767959","title":"福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160767959","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160767959?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"福泰制药今日宣布，其候选药物Inaxaplin在针对APOL1介导肾病其他患者群体的2B期AMPLIFIED研究中，取得了令人鼓舞的积极数据。与此同时，公司还确认，备受瞩目的2/3期AMPLITUDE注册试验已顺利达成全部患者入组目标。目前，该疾病在全球范围内缺乏针对性治疗手段，Inaxaplin有望为患者带来突破性的治疗选择。业内分析人士认为，AMPLIFIED研究的积极结果以及AMPLITUDE试验的顺利入组，进一步巩固了福泰制药在肾脏病精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0109394709.USD","LU1035775433.USD","LU1069344957.HKD","LU2468319806.SGD","LU1093756325.SGD","IE0009355771.USD","BK4532","SG9999013999.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z9Z06.USD","IE00B19Z3581.USD","BK4585","BK4588","LU1778281490.HKD","LU1674673691.USD","LU0079474960.USD","IBB","IE00BJJMRZ35.SGD","LU2362541273.HKD","IE0002141913.USD","IE00B2B36J28.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1674673428.USD","LU2456880835.USD","IE00B19Z3B42.SGD","SG9999001176.USD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU0432979614.USD","GNMX","LU2324357040.USD","TBXU","BK4139","LU2462157665.USD","LU2362541513.USD","LU1430594728.SGD","LU2362540622.SGD","LU0234570918.USD","LU2417539215.USD","LU2089984988.USD","BBH","LU0061475181.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191181268","title":"福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1191181268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191181268?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 20:01","pubTimestamp":1790078474,"startTime":"0","endTime":"0","summary":"生物制药巨头福泰制药近日披露了一项令人瞩目的临床数据：其候选药物Inaxaplin在治疗伴有适度蛋白尿的常染色体显性多囊肾病患者中，于第13周时使尿白蛋白肌酐比较基线大幅下降42.7%。值得关注的是，这项数据凸显了Inaxaplin在降低蛋白尿方面的显著潜力，而蛋白尿正是衡量肾脏损伤程度及预测疾病进展风险的关键生物标志物。尽管现有数据展现出鼓舞人心的信号，但业界普遍认为，要全面评估Inaxaplin的长期获益与安全性，尚需更大规模、更长周期的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1585245621.USD","BK4139","IE00B2B36J28.USD","LU2236285917.USD","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","SG9999001176.SGD","BBH","BK4588","LU0109394709.USD","LU2468319806.SGD","LU2362540622.SGD","IE0002270589.USD","VRTX","BK4585","LU0079474960.USD","LU2456880835.USD","GNMX","IBB","LU2362541513.USD","LU0256863811.USD","BIB","LU0234570918.USD","SG9999001176.USD","BK4533","SG9999013999.USD","LU0823416689.USD","IE00B19Z9P08.USD","TBXU","IBBQ","LU0061475181.USD","LU2462157665.USD","IDNA","LU2237438978.USD","LU0417517546.SGD","BK4567","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","LU0432979614.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1674673428.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1778281490.HKD","SGXZ57979304.SGD","LU1674673691.USD","LU2324357040.USD","LU1430594728.SGD","LU2089984988.USD","LU2362541273.HKD","PBE","IE00BJJMRZ35.SGD","LU1035775433.USD","LU1069344957.HKD","IE00B19Z3B42.SGD","IE00B894F039.SGD","BK4532","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169682?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0102","BIOY","BK4585","BK0070","PBE","GSKH","IBB","BK0251","WRND","BK0155","GDOC","BBP","600499","BK0188","BK4588","600721","BK0216","XLVI","SETM","LFSC","APXH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147475205","title":"福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147475205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147475205?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:04","pubTimestamp":1789985058,"startTime":"0","endTime":"0","summary":"Leerink Partners近日宣布恢复对福泰制药的覆盖研究，并给予该股\"跑赢大盘\"评级。这家华尔街投行同时将目标价设定为594美元，彰显其对福泰制药未来走势的乐观预期。这一动作引发市场广泛关注——毕竟，Leerink Partners在生物医药领域的分析素以严谨著称。其恢复覆盖并给出积极评级，无疑为投资者注入了一针强心剂。值得注意的是，这一评级决定恰逢生物科技板块整体回暖之际。多重因素交织下，福泰制药的股价表现或将迎来新的催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU2324357040.USD","LU0061475181.USD","LU2417539215.USD","LU0058720904.USD","VRTX","BBH","LU2462157665.USD","LU0432979614.USD","LU1585245621.USD","LU2362541273.HKD","IE00B894F039.SGD","LU1093756168.USD","IE00BFTCPJ56.SGD","BK4588","LU1035775433.USD","IE0002141913.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","LU1093756325.SGD","SGXZ57979304.SGD","IE00B19Z9Z06.USD","LU1778281490.HKD","LU1674673428.USD","IE00BZ9MQY76.HKD","IE00B19Z3581.USD","LU0823416689.USD","LU2236285917.USD","LU2468319806.SGD","SG9999013999.USD","LU0109394709.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B4R5TH58.HKD","LU1674673691.USD","BK4533","LU0256863811.USD","LU2456880835.USD","IBB","LU0079474960.USD","LU1430594728.SGD","BK4567","LU2237438978.USD","BK4585","TBXU","BK4532","IE00BJT1NW94.SGD","IBBQ","IDNA","LU0417517546.SGD","LU2089984988.USD","LU0234570918.USD","LU1069344957.HKD","LU0889565916.HKD","SG9999001176.USD","IE00BJJMRZ35.SGD","SG9999001176.SGD","PBE","LU2362541513.USD","LU0320765992.SGD","BK4139","GNMX","LU2362540622.SGD","LU0289739699.SGD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669137049?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SBIO","IBBQ","GDOC","WRND","GSKH","BIOY","LFSC","APXH","XLVI","IBB","MEDX","BK1161","BK4585","159992","06978","BK4588","BBP","LNGR","BK1574","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668916276","title":"专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668916276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668916276?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":"美国因此面临着一个巨大的“生物类似药空窗”，这可能导致1890亿美元的医疗成本节约空间流失。据AAM统计，去年仿制药与生物类似药合计为美国节约医疗开支4960亿美元，较2024年增加300亿美元;其中仿制药贡献了95%的节约额。AAM表示，生物类似药的研发主要瞄准市场潜力大、专利即将到期的生物药。那些专利到期前年销售额超10亿美元的原研药，对应的生物类似药竞争尤为激烈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1992135399.USD","LU2272731782.SGD","PPH","LU2322448957.HKD","LU2473716301.USD","159891","IE00B5TLWC47.USD","XPH","LU1992135472.HKD","LU2272731600.USD","BK4588","LU2272731865.HKD","LU2322448791.USD","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668162209","title":"专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668162209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668162209?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","LU1992135399.USD","LU2272731782.SGD","XPH","PPH","LU2473716301.USD","BK4585","LU2322448957.HKD","BK4588","LU2322448791.USD","IBB","LU2272731600.USD","LU1992135472.HKD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科学扩大六项免许可费自愿授权协议，力推每年一次HIV预防药Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU1057294990.SGD","LU0965509010.AUD","BK4588","BMED","LU0861579265.USD","LU1934455863.HKD","LU1037948541.HKD","LU2357627491.SGD","LU2112291526.USD","BK4139","IE00BSNM7G36.USD","IE00B19Z3581.USD","LU0882574055.USD","LU0965509283.SGD","LU0109394709.USD","LU1674673428.USD","LU1839511570.USD","BIB","IE00BZ1G4Q59.USD","LU0823416689.USD","LU1934455277.USD","LU1061106388.HKD","SG9999015952.SGD","SG9999015945.SGD","IE0002270589.USD","LU0965508806.USD","BK4585","LU2089984988.USD","TBXU","LU1934455194.USD","LU1778281490.HKD","BK4566","LU0320765992.SGD","LU1430594728.SGD","BK4568","BK4583","LU1571399168.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU1066051498.USD","LU1585245621.USD","IBB","LU1037948897.HKD","LU2468319806.SGD","BK4578","BBH","MEDI","SG9999015986.USD","LU2087621335.USD","TMED","BK4550","IE00BKVL7J92.USD","LU0289739699.SGD","GILD","LU1023059063.AUD","LU0859254822.USD","LU0122379950.USD","LU1066053197.SGD","IE00B3T34201.USD","LU0965509101.SGD","LU0058720904.USD","BK4532","LU1674673691.USD","IBBQ","SG9999015978.USD","LU0234570918.USD","LU0114720955.EUR","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667074086","title":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2667074086","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667074086?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556485,"startTime":"0","endTime":"0","summary":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发Kunal Das/Siddhi Mahatole路透9月16日-药物研发公司Sling Therapeutics周三表示，已筹集1.23亿美元，用于推进其用于治疗甲状腺眼病的实验性口服药物的后期临床试验。该疾病会导致眼周发炎和肿胀，进而可能引发眼球突出和视力丧失。作为此次融资协议的一部分，Sling还任命了Forbion的Regina Salvat和Sectoral Asset Management的Franois Beaubien加入其董事会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4T4580NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","TBXU","SG9999001440.SGD","AMGN","IE00B4R5TH58.HKD","PJP","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IBBQ","LU1057294990.SGD","LU2112291526.USD","BK4533","PBE","BK4581","IE00B2B36J28.USD","VRDN","LU2242646821.SGD","LU2242652126.USD","LU2468319806.SGD","LU1571399168.USD","BIB","LU0289739699.SGD","BBH","IE0009355771.USD","BK4585","LU1983299246.USD","IE00BJT1NW94.SGD","BK4588","LU0058720904.USD","BK4139","LU1023059063.AUD","LU0109394709.USD","BK4534","BK4599","IBB","LU0868494617.USD","LU2089984988.USD","LU1061106388.HKD","LU0122379950.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667267605?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0109394709.USD","BK4534","BBH","IBBQ","LU1883839398.USD","PBE","LU1236620834.HKD","BK4139","XPH","IHE","IBB","BK4588","LU1261432733.SGD","TBXU","LU2125154778.USD","LU2473716301.USD","LU1992135399.USD","LU0320765992.SGD","BK4585","LU0114720955.EUR","BMY","FTXH","LU0058720904.USD","BK4559","IE00BSNM7G36.USD","PJP","IE0009355771.USD","BIB","LU1983299246.USD","LU0225771236.USD","LU0868494617.USD","LU1023059063.AUD","LU1868837300.USD","LU1989771016.USD","LU0289739699.SGD","LU1868836757.USD","LU2272731865.HKD","LU2468319806.SGD","PPH","BK4566","LU0061475181.USD","IE00B4R5TH58.HKD","AMGN","BK4533","LU1236620750.USD","LU2322448957.HKD","LU1670711123.USD","LU0225284248.USD","LU1868836591.USD","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667629132","title":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629132","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629132?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 01:29","pubTimestamp":1789493363,"startTime":"0","endTime":"0","summary":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进Blake Brittain路透9月15日-百时美施贵宝公司和小野制药公司已在特拉华州联邦法院起诉安进公司，试图阻止安进公司在美国推出其畅销癌症免疫疗法药物“欧迪沃”的生物类似药。百时美施贵宝和小野制药的发言人尚未立即回应置评请求。共同开发“欧狄沃”的百时美施贵宝和小野制药指控，安进的生物类似药将侵犯该药物所涉及的七项美国专利，并请求法院在专利有效期内禁止该生物类似药的销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T4571DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0267386448.USD","BK4559","LU0237698245.USD","LU1585245621.USD","LU1057294990.SGD","IBBQ","LU1261432733.SGD","LU1670711040.USD","LU0061475181.USD","LU2242652126.USD","LU1323610961.USD","LU2112291526.USD","LU1093756168.USD","BK4581","LU0058720904.USD","LU0456855351.SGD","IE0009355771.USD","LU2125154778.USD","IE00BFXG1179.USD","LU0289739699.SGD","LU1868836914.USD","IBB","LU2125154935.USD","BIB","LU0225284248.USD","04332","BK4532","LU1670711123.USD","BK4007","IE00B4R5TH58.HKD","LU0889565916.HKD","LU0306806265.USD","IHE","LU1883839398.USD","LU0321505439.SGD","LU1868836757.USD","IE00BJJMRZ35.SGD","BK4139","LU0225771236.USD","LU2133065610.SGD","BK4533","LU1430594728.SGD","BMY","BK4566","LU0320765992.SGD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU1718418525.SGD","LU1023059063.AUD","LU1032466523.USD","LU0321505868.SGD","LU1868836591.USD","LU1670710588.SGD","LU1989771016.USD","LU1236620834.HKD","LU1983299246.USD","AMGN","LU1670710661.SGD","BK4599","LU0122379950.USD","LU0985481810.HKD","LU0109394709.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4588","SG9999001440.SGD","PJP","PBE","LU2360032135.SGD","LU0432979614.USD","LU1571399168.USD","BK4585","LU2596442595.SGD","BK4534","LU0306807586.USD","FTXH","LU1236620750.USD","BBH","IE0002141913.USD","LU1868837300.USD","LU0868494617.USD","IE00B2B36J28.USD","TBXU","LU1093756325.SGD","LU2089984988.USD","IE00BSNM7G36.USD","LU1074936037.SGD","LU0096364046.USD","LU1868837136.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科学携手巴西卫生部，共促Lenacapavir本地化生产新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","BK4566","LU1778281490.HKD","SG9999015978.USD","BK4550","IE00B19Z3B42.SGD","LU0859254822.USD","LU2468319806.SGD","LU1066053197.SGD","IBBQ","LU0861579265.USD","BK4585","IE00BKVL7J92.USD","LU0122379950.USD","LU0965509101.SGD","LU1934455277.USD","LU1934455863.HKD","LU2087621335.USD","BK4588","BK4578","LU1839511570.USD","BK4139","LU2089984988.USD","LU1057294990.SGD","SG9999015945.SGD","LU1674673691.USD","TBXU","BIB","LU1037948541.HKD","LU0320765992.SGD","LU0965508806.USD","LU1066051498.USD","MEDI","LU0058720904.USD","LU1585245621.USD","BK4568","BK4532","BBH","IE00B19Z3581.USD","IBB","LU0889565916.HKD","LU1023059063.AUD","LU1430594728.SGD","LU2357627491.SGD","LU0882574055.USD","GILD","LU1037948897.HKD","LU1934455194.USD","TMED","BK4583","LU1674673428.USD","LU1571399168.USD","IE00B7SZLL34.SGD","LU1061106388.HKD","LU0289739699.SGD","LU0965509010.AUD","LU2324357040.USD","LU0823416689.USD","SG9999015986.USD","SG9999015952.SGD","LU0965509283.SGD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","BMED","LU0109394709.USD","LU2112291526.USD","IE0002270589.USD","LU0234570918.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科学：持续探索与泛美卫生组织合作，助力各国准备好并扩大长效艾滋病预防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1066053197.SGD","BK4566","BK4578","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1778281490.HKD","LU1934455194.USD","LU2468319806.SGD","IBB","IE00BSNM7G36.USD","LU0109394709.USD","LU1037948541.HKD","LU0234570918.USD","LU1037948897.HKD","BK4583","LU0882574055.USD","GILD","IE00BKVL7J92.USD","BK4532","LU0889565916.HKD","LU0320765992.SGD","LU0861579265.USD","LU1061106388.HKD","LU1430594728.SGD","LU1571399168.USD","LU2089984988.USD","IE00B19Z3581.USD","BK4585","LU0965509283.SGD","SG9999015986.USD","LU1934455277.USD","TBXU","BK4568","IBBQ","LU0859254822.USD","LU1023059063.AUD","LU0122379950.USD","LU0114720955.EUR","BMED","SG9999015978.USD","LU2324357040.USD","TMED","LU1585245621.USD","LU2357627491.SGD","LU0965509010.AUD","SG9999015952.SGD","BK4550","LU1674673428.USD","LU0965508806.USD","IE00B19Z3B42.SGD","LU0823416689.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","BBH","SG9999015945.SGD","LU1057294990.SGD","LU1839511570.USD","LU1066051498.USD","LU1674673691.USD","BK4139","BIB","MEDI","IE0002270589.USD","LU0058720904.USD","LU0965509101.SGD","LU1934455863.HKD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科学公司高管在电话会议上表示，HIV药物市场的增长预计将在未来几个季度内回归至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623020?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0965509283.SGD","LU0889565916.HKD","LU1037948541.HKD","TBXU","LU2324357040.USD","LU1037948897.HKD","LU0114720955.EUR","SG9999015945.SGD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1674673428.USD","IBBQ","IE00B7SZLL34.SGD","LU0859254822.USD","LU1057294990.SGD","LU2112291526.USD","MEDI","BK4550","LU0965509101.SGD","TMED","LU1839511570.USD","BK4568","LU1585245621.USD","BIB","LU0289739699.SGD","BBH","SG9999015952.SGD","BMED","LU1674673691.USD","LU0058720904.USD","BK4588","BK4532","BK4139","LU1066051498.USD","SG9999015978.USD","IE00BKVL7J92.USD","LU1430594728.SGD","LU1066053197.SGD","GILD","IBB","IE0002270589.USD","LU1934455863.HKD","LU1061106388.HKD","LU0122379950.USD","IE00B19Z3581.USD","LU0965509010.AUD","LU1934455277.USD","LU0882574055.USD","LU0234570918.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062306","title":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062306","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062306?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485029,"startTime":"0","endTime":"0","summary":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致路透9月15日-美国制药公司吉利德科学GILD.O周二表示，已与泛美卫生组织达成协议，将在拉丁美洲和加勒比地区扩大其艾滋病预防药物的可及性，以帮助这些地区遏制新发感染。吉利德公司指出，2010年至2024年间，拉丁美洲和加勒比地区的新发艾滋病毒感染病例增加了13%，并归因于艾滋病毒预防药物使用方面的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45714A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","TMED","BBH","IBBQ","LU1061106388.HKD","LU0058720904.USD","LU1037948897.HKD","LU1066051498.USD","LU1674673691.USD","LU2112291526.USD","LU2324357040.USD","BK4532","BK4139","IE00B7SZLL34.SGD","LU0859254822.USD","LU1839511570.USD","BK4588","LU0889565916.HKD","IE00BKVL7J92.USD","LU1585245621.USD","GILD","IE0002270589.USD","SG9999015945.SGD","BIB","BMED","LU0289739699.SGD","IBB","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1037948541.HKD","LU1057294990.SGD","MEDI","LU1934455863.HKD","LU0882574055.USD","BK4566","LU0320765992.SGD","LU0965509283.SGD","LU1430594728.SGD","SG9999015952.SGD","BK4568","LU0234570918.USD","LU1674673428.USD","LU0965509010.AUD","LU1934455277.USD","SG9999015978.USD","LU0122379950.USD","LU0965509101.SGD","BK4550","LU1066053197.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科学携手泛美卫生组织，加速拉美及加勒比地区HIV预防药物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK4550","LU0114720955.EUR","LU1934455194.USD","IE00B19Z3581.USD","LU2112291526.USD","BK4578","LU1571399168.USD","LU0889565916.HKD","LU0859254822.USD","IE00BKVL7J92.USD","TMED","BK4566","BBH","BK4139","LU0320765992.SGD","LU1674673428.USD","LU0965509283.SGD","LU2468319806.SGD","BK4583","IE00B19Z3B42.SGD","LU0058720904.USD","LU0965508806.USD","LU1066053197.SGD","BK4532","LU1061106388.HKD","LU1057294990.SGD","LU0882574055.USD","LU0234570918.USD","LU1037948541.HKD","LU0861579265.USD","LU1066051498.USD","LU2089984988.USD","BIB","LU1674673691.USD","BMED","SG9999015986.USD","LU2324357040.USD","LU1934455863.HKD","LU0122379950.USD","BK4568","LU1839511570.USD","IBB","LU1934455277.USD","TBXU","IBBQ","IE0002270589.USD","LU0823416689.USD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1778281490.HKD","GILD","IE00B3T34201.USD","BK4588","LU2087621335.USD","BK4585","LU1430594728.SGD","LU0289739699.SGD","LU2357627491.SGD","MEDI","LU0109394709.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","SG9999015952.SGD","LU1037948897.HKD","LU0965509010.AUD","SG9999015978.USD","LU1023059063.AUD","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未来几个季度HIV市场增长或将回归2%-3%常态水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B19Z3B42.SGD","BBH","IBBQ","LU0122379950.USD","LU1934455194.USD","BK4139","LU2087621335.USD","LU1674673691.USD","IE00B19Z3581.USD","LU2112291526.USD","TMED","IBB","LU0861579265.USD","BK4588","LU0965509101.SGD","IE00BKVL7J92.USD","LU1061106388.HKD","SG9999015986.USD","TBXU","SG9999015978.USD","LU0965508806.USD","IE0002270589.USD","LU0320765992.SGD","LU0859254822.USD","BK4585","IE00B7SZLL34.SGD","LU0114720955.EUR","LU0889565916.HKD","LU0058720904.USD","LU1037948897.HKD","MEDI","LU1934455277.USD","IE00BSNM7G36.USD","LU0882574055.USD","BIB","LU1571399168.USD","BMED","LU1585245621.USD","LU0823416689.USD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1674673428.USD","BK4583","LU1023059063.AUD","LU2089984988.USD","BK4550","LU0289739699.SGD","LU1430594728.SGD","LU2357627491.SGD","SG9999015952.SGD","LU1066053197.SGD","LU1057294990.SGD","LU2468319806.SGD","LU1839511570.USD","BK4566","BK4568","LU1037948541.HKD","SG9999015945.SGD","LU0965509010.AUD","BK4532","LU2324357040.USD","LU1066051498.USD","LU1934455863.HKD","LU0965509283.SGD","BK4578","LU1778281490.HKD","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV预防药物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","BK4585","LU2324357040.USD","LU0289739699.SGD","IE00B3T34201.USD","LU0109394709.USD","LU1674673691.USD","LU0889565916.HKD","LU2087621335.USD","MEDI","LU0122379950.USD","LU1023059063.AUD","LU1934455194.USD","LU0823416689.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","BBH","GILD","BK4588","LU1778281490.HKD","BK4583","LU0965509010.AUD","LU1037948541.HKD","IE00BSNM7G36.USD","LU0965508806.USD","LU2112291526.USD","TMED","LU0234570918.USD","BK4566","LU1061106388.HKD","BK4532","IE0002270589.USD","LU1934455863.HKD","BIB","BMED","LU1057294990.SGD","BK4550","TBXU","IBBQ","LU1839511570.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU1934455277.USD","LU0861579265.USD","LU2357627491.SGD","LU0058720904.USD","LU1037948897.HKD","SG9999015986.USD","LU1066053197.SGD","LU1571399168.USD","LU1674673428.USD","BK4568","LU1066051498.USD","BK4139","LU1430594728.SGD","SG9999015945.SGD","LU0882574055.USD","LU0965509283.SGD","IE00BKVL7J92.USD","LU0965509101.SGD","IBB","LU0859254822.USD","LU2089984988.USD","SG9999015978.USD","BK4578","IE00B19Z3581.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}